Sara
Villar Fernández
Colaboradora Clínica
Hospital Duran i Reynals
Barcelona, España
Publications in collaboration with researchers from Hospital Duran i Reynals (5)
2025
-
Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
Blood Cancer Journal, Vol. 15, Núm. 1
-
Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC
Frontiers in Immunology, Vol. 16
-
Early cardiac events after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. subanalysis exploring cardiac toxicity conducted on behalf of GETH-TC
Frontiers in Immunology, Vol. 16
-
Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation
Cancers, Vol. 17, Núm. 19
2024
-
Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC
Bone Marrow Transplantation, Vol. 59, Núm. 12, pp. 1694-1703